What Aviptadil is
Aviptadil is a vasoactive intestinal peptide analog investigated in pulmonary and critical-care contexts.
Aviptadil is grouped under Approved / Clinical / Endogenous / Biology on PeptideFactCheck because it became widely discussed when pulmonary peptide therapeutics briefly moved into public view.
The useful starting point is to separate the molecule itself from the internet story around it. It became widely discussed when pulmonary peptide therapeutics briefly moved into public view.
Why people keep looking it up
It became widely discussed when pulmonary peptide therapeutics briefly moved into public view.
Aviptadil is a vasoactive intestinal peptide analog investigated in pulmonary and critical-care contexts.
Aviptadil tends to stay in the conversation because it touches a familiar public theme: vip analog, pulmonary signaling, and inflammation context. That makes it easy for the claim to travel faster than the evidence.
What the evidence can support right now
Clinical-stage peptide with human data but no approved label in this record.
Human investigation exists, but this remains investigational rather than an approved mainstream therapy in the current record.
Mechanistic support follows VIP-related pulmonary and inflammatory signaling.
Why this page carries the current tier: Clinical-stage peptide with human data but no approved label in this record.
The current seed trail for Aviptadil is pulling from 1 literature source, 1 trials source, and 1 databases source.
Safety, limits, and regulatory context
Critical-care peptide stories can get distorted when stripped out of their actual clinical context.
Aviptadil remains investigational in the current seed set.
Editorial boundary: PeptideFactCheck does not publish dosing, cycling, sourcing, injection, or administration instructions for Aviptadil. The job here is to explain the public claim, the mechanism story, the evidence strength, and the current limits.
Molecular and identifier data
The current PubChem match for Aviptadil is CID 16132300. That gives the page a source-backed chemistry record rather than a placeholder identifier block.
- PubChem CID
- 16132300
- Formula
- C147H237N43O43S
- Molecular weight
- 3326.8
- InChIKey
- VBUWHHLIZKOSMS-RIWXPGAOSA-N
Matched synonyms include invicorp, Vip human vip, Vasoactive intestinal octacosapeptide, RLF-100, A67JUW790C, Porcine vasoactive intestinal octacosapeptide, Zyesami, L-Histidyl-L-seryl-L-aspartyl-L-alanyl-L-valyl-L-phenylalanyl-L-threonyl-L-aspartyl-L-asparaginyl-L-tyrosyl-L-threonyl-L-arginyl-L-leucyl-L-arginyl-L-lysyl-L-glutaminyl-L-methionyl-L-alanyl-L-valyl-L-lysyl-L-lysyl-L-tyrosyl-L-leucyl-L-asparaginyl-L-seryl-L-isoleucyl-L-leucyl-L-asparagine.
Open PubChem recordClinical trial snapshot
The current ClinicalTrials.gov intervention query for Aviptadil returns 9 study records. This does not prove efficacy by itself, but it does show whether the peptide is showing up in a formal trial registry rather than only in forums or vendor copy.
Literature snapshot
The current PubMed query for Aviptadil returns 68 results. The articles below are a quick literature surface so the page shows actual papers instead of only generic evidence labels.
Source trail
Each linked source is shown directly so the page can be audited. The page now combines its editorial seed trail with automated official-source enrichment generated on 2026-04-24 from PubChem, ClinicalTrials.gov, PubMed, DailyMed, openFDA label, and Drugs@FDA.